Activity Number and Title
22HT57252 - Gene Therapy for Providers 101
October 14, 2022
5:00 PM Eastern, October 13, 2023
The estimated time to complete this enduring material is 45 minutes.
The purpose of this activity is to enable learners to develop basic knowledge of gene therapy for hemophilia, thereby enhancing learner competence to discuss gene therapy with patients who may benefit from this emerging treatment.
This learning activity provides basic education on hemophilia gene therapy, including the aims of gene therapy; the packaging, delivery, and activity of the replacement genes; and the means by which the replacement genes lead to production and/or availability of normal clotting factor in persons with hemophilia. The module will also review information that may be particularly important when discussing hemophilia gene therapy with patients, such as knowledgeable informed consent, outcomes data, and potential risks and benefits.
This accredited continuing education activity is designed for multidisciplinary providers at hemophilia treatment centers, including nurses, physicians, pharmacists, physical therapists, social workers, and genetic counselors providing care to persons with hemophilia A and hemophilia B.
At the conclusion of this activity, the participants should be better able to:
- Describe a pathway to preparedness for gene therapy from education of the multidisciplinary healthcare team to clinical delivery
- Provide an overview of the goal of gene therapy for hemophilia
- Explain the elements of gene therapy (i.e. packaging, administration, mechanism of action)
- Define the profile of gene therapy candidates with FVIII deficiency and FIX deficiency
- Review known adverse effects from completed and ongoing clinical trials
- Articulate critical considerations for the multidisciplinary healthcare team in providing care for patients receiving gene therapy
- Discuss issues related to obtaining knowledgeable informed consent and counseling patients
- Steven W. Pipe, MD
- Shelley Crary, MD, MSCS
Requirements for Successful Completion
In order to receive continuing education credits, you must complete these steps prior to the activity expiration date.
- Read the Disclosure Information found in the To Dos section.
- Complete the learning activity
- Complete the evaluation
- Complete the post-test with a score of 70% or better
- Upon successful completion of the post-test your certificate of completion will be available to print or save
Accreditation Statement and Contact Hours
In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Indiana Hemophilia & Thrombosis Center. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The University of Nebraska Medical Center designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The University of Nebraska Medical Center designates this activity for 0.75 ACPE contact hours. Pharmacists should claim only the credit commensurate with the extent of their participation in the activity. Credit will be provided to NABP CPE Monitor within 60 days after the activity completion. UAN # JA0000319-9999-22-018-H01-P
The University of Nebraska Medical Center designates this activity for 0.75 ANCC contact hours. Nurses should only claim credit for the actual time spent participating in the activity.
No commercial support was received for this activity.
- 2 gigabytes of RAM
- High-speed internet connection
- Internet browser (current version) Firefox, Safari, Chrome, or Explorer